Pacira BioSciences, Inc. (PCRX) Bundle
Ever wondered about the company revolutionizing pain management with non-opioid therapies? Pacira BioSciences, Inc. (PCRX), with a market capitalization of $1.14 billion and $701 million in revenue for 2024, is making waves in the pharmaceutical industry. Keep reading to discover the history, ownership structure, mission, and how this innovative company operates and generates revenue, driving its commitment to transforming lives through effective, non-opioid pain management solutions.
Pacira BioSciences, Inc. (PCRX) History
Pacira BioSciences Founding Timeline
Year established
Pacira Pharmaceuticals, Inc. was established in 2006.
Original location
The company is headquartered in Parsippany, New Jersey.
Founding team members
While specific names of the original founding team members are not widely publicized in available resources, the company's leadership has been crucial to its growth and strategic direction.
Initial capital/funding
Information regarding the initial capital and funding for Pacira BioSciences' founding is not readily available in the provided search results.
Pacira BioSciences Evolution Milestones
| Year | Key Event | Significance |
|---|---|---|
| 2011 | FDA Approval of EXPAREL | Received FDA approval for EXPAREL (bupivacaine liposome injectable suspension) for single-dose administration into the surgical site to produce postsurgical analgesia. |
| 2012 | Commercial Launch of EXPAREL | EXPAREL was commercially launched in the U.S., marking a significant step in providing a non-opioid option for pain management after surgery. |
| 2014 | Acquisition of SkyePharma's San Diego Facility | Pacira acquired SkyePharma's San Diego manufacturing facility, enhancing its manufacturing capabilities. |
| 2016 | EXPAREL Label Expansion | The FDA approved an expanded label for EXPAREL to include nerve block administration, broadening its utility in pain management. |
| 2019 | Acquisition of MyoScience | Pacira acquired MyoScience, the maker of the iovera system, a non-opioid pain management option that uses cryoanalgesia. |
| 2021 | Acquisition of Flexion Therapeutics | Pacira BioSciences acquired Flexion Therapeutics, gaining access to ZILRETTA, an intra-articular, extended-release, corticosteroid injection for osteoarthritis knee pain. This acquisition significantly expanded Pacira's portfolio in non-opioid pain management. |
| 2023 | Continued Growth and Expansion | Pacira continued to experience growth, driven by the increasing adoption of EXPAREL and other products in its portfolio. The company focused on expanding its market presence and developing new applications for its existing products. |
Pacira BioSciences Transformative Moments
- FDA Approval and Launch of EXPAREL: The FDA approval and subsequent commercial launch of EXPAREL in 2012 was a transformative moment. It established the company as a leader in non-opioid pain management.
- Strategic Acquisitions: Acquisitions such as MyoScience in 2019 and Flexion Therapeutics in 2021 significantly broadened Pacira's product offerings and market reach.
- Label Expansion for EXPAREL: The label expansion for EXPAREL to include nerve block administration enhanced its clinical utility and market potential.
For insights into the company's guiding principles, explore: Mission Statement, Vision, & Core Values of Pacira BioSciences, Inc. (PCRX).
Pacira BioSciences, Inc. (PCRX) Ownership Structure
Understanding the ownership structure of Pacira BioSciences, Inc. provides insights into who controls the company and whose interests might be driving its strategic decisions. The company has a mix of institutional, retail, and insider ownership, which shapes its governance and direction.
Pacira BioSciences, Inc. Current Status
Pacira BioSciences, Inc. is a public company, meaning its shares are traded on a stock exchange, and it is subject to regulations and reporting requirements. As a publicly traded entity, its ownership is distributed among various shareholders, including institutions, individual investors, and company insiders.
Pacira BioSciences, Inc. Ownership Breakdown
Pacira BioSciences, Inc.'s ownership is distributed among various types of shareholders. Here is a breakdown:
| Shareholder Type | Ownership, % | Notes |
|---|---|---|
| Institutional Owners | 96.42% | Institutional investors, such as mutual funds, pension funds, and hedge funds, hold a significant percentage of Pacira BioSciences, Inc.'s shares. This substantial ownership indicates strong interest and confidence from major financial institutions. |
| Insider Ownership | 0.52% | Insiders, including officers and directors, own a small percentage of the company. This suggests that the leadership's interests are aligned with the shareholders to some extent. |
| Retail Investors | 3.06% | Retail investors, or individual shareholders, hold a minority stake in Pacira BioSciences, Inc. |
Pacira BioSciences, Inc. Leadership
The leadership team at Pacira BioSciences, Inc. is responsible for the strategic direction and operational management of the company. Key members of the leadership team include:
- Frank D. Calderoni: Interim Chief Executive Officer
- Ronald J. Ellis: Chief Financial Officer
- Brian M. Eastwood: Chief Marketing Officer
Understanding Pacira BioSciences, Inc.'s financial health is crucial for investors. For a detailed analysis, check out: Breaking Down Pacira BioSciences, Inc. (PCRX) Financial Health: Key Insights for Investors
Pacira BioSciences, Inc. (PCRX) Mission and Values
Pacira BioSciences strives to provide novel medicines and drug delivery systems that improve patient care. The company is committed to innovation and making a positive impact on healthcare.
Pacira BioSciences, Inc. Core Purpose
Official mission statement
Pacira BioSciences, Inc.'s mission statement is: 'To provide innovative solutions that enhance patient outcomes and experiences.'
- Focuses on developing and commercializing novel pharmaceutical products.
- Aims to address unmet medical needs in areas such as pain management and postsurgical recovery.
- Dedicated to improving the overall quality of patient care through its products and initiatives.
Vision statement
While a specific, formally declared vision statement is not readily available, insights into the vision of Pacira BioSciences, Inc. can be inferred from their strategic goals and company activities.
- To be a leader in the non-opioid pain management space, offering alternatives to traditional pain relief methods.
- Expanding the applications and reach of their existing products, such as EXPAREL, and developing new innovative products.
- To drive significant advancements in patient care, particularly in reducing reliance on opioids and improving recovery times.
Company slogan/tagline
Information on a specific, official slogan or tagline for Pacira BioSciences, Inc. is not widely available. However, themes and messages frequently associated with the company include:
- Advancing patient care through innovative solutions.
- Focusing on non-opioid options for pain management.
- Improving postsurgical recovery and patient outcomes.
To gain more insights into Pacira BioSciences, Inc. (PCRX) financial performance, see this analysis: Breaking Down Pacira BioSciences, Inc. (PCRX) Financial Health: Key Insights for Investors
Pacira BioSciences, Inc. (PCRX) How It Works
Pacira BioSciences, Inc. focuses on developing, commercializing, and acquiring novel pharmaceutical products, primarily in the areas of postsurgical pain management and regenerative health solutions.
Pacira BioSciences, Inc.'s Product/Service Portfolio
| Product/Service | Target Market | Key Features |
|---|---|---|
| EXPAREL® (bupivacaine liposome injectable suspension) | Patients undergoing surgery for postsurgical pain management. |
|
| ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) | Patients with osteoarthritis knee pain. |
|
| iovera° system | Physicians treating patients with peripheral nerve pain. |
|
Pacira BioSciences, Inc.'s Operational Framework
Pacira BioSciences, Inc. operates through a focused commercial and operational strategy to deliver its products to the market. This involves:
- Research and Development: Investing in the development of new formulations and expanding the applications of existing products.
- Manufacturing: Utilizing advanced manufacturing processes to ensure product quality and scalability.
- Sales and Marketing: Employing a targeted sales force to reach surgeons, anesthesiologists, and other healthcare providers.
- Distribution: Working with distributors to ensure broad access to their products in hospitals and surgical centers.
- Acquisitions: Acquiring complementary products and technologies to expand their portfolio and market reach.
More insights about the company can be found here: Mission Statement, Vision, & Core Values of Pacira BioSciences, Inc. (PCRX).
Pacira BioSciences, Inc.'s Strategic Advantages
Pacira BioSciences, Inc. has several strategic advantages that contribute to its market position:
- Proprietary Technology: DepoFoam® technology provides a distinct advantage in creating long-acting formulations.
- Market Leadership: EXPAREL® has established a strong presence in the postsurgical pain management market.
- Diversified Portfolio: Offering a range of products that address different types of pain and patient needs.
- Strong Commercial Capabilities: A well-established sales and marketing infrastructure that supports product adoption.
- Focus on Non-Opioid Pain Management: Addressing the growing demand for alternatives to opioid pain medications.
Pacira BioSciences, Inc. (PCRX) How It Makes Money
Pacira BioSciences, Inc. generates revenue primarily through the development, commercialization, and manufacture of pharmaceutical products, particularly in the areas of pain management and regenerative health.
Pacira BioSciences, Inc.'s Revenue Breakdown
| Revenue Stream | % of Total | Growth Trend |
|---|---|---|
| EXPAREL (bupivacaine liposome injectable suspension) | Approximately 80-85% | Increasing |
| iovera° system | Approximately 10-15% | Increasing |
| Other Products and Royalties | Approximately 5% | Stable |
Pacira BioSciences, Inc.'s Business Economics
Pacira BioSciences, Inc.'s business economics are centered on:
- Pricing Strategy: Premium pricing for innovative, non-opioid pain management solutions like EXPAREL. The pricing reflects the clinical benefits, reduced opioid use, and potential for faster patient recovery.
- Market Demand: Driven by increasing awareness of opioid-related risks and the desire for effective, non-addictive pain relief options.
- Cost Structure: Significant investment in research and development, clinical trials, and manufacturing to maintain a competitive edge and meet regulatory standards.
- Reimbursement Landscape: Navigating the complexities of healthcare reimbursement to ensure market access and favorable pricing for its products.
Pacira BioSciences, Inc.'s Financial Performance
Key aspects of Pacira BioSciences, Inc.'s financial performance include:
- Revenue Growth: Primarily driven by EXPAREL, with consistent increases in sales volume and market penetration. For example, in 2024, EXPAREL net product revenue was $671.2 million, an increase of 10% compared to 2023.
- Gross Margin: High gross margins, typically above 70%, reflecting the proprietary nature of its products and efficient manufacturing processes.
- Operating Expenses: Significant investment in sales and marketing to drive product adoption, as well as research and development for new product development and clinical studies.
- Net Income/Loss: Fluctuations based on product sales, R&D expenses, and strategic investments.
- Cash Flow: Strong cash flow generation from operations, supporting continued investment in growth initiatives and potential acquisitions.
To gain more insights into Pacira BioSciences, Inc.'s investors and their motivations, explore this resource: Exploring Pacira BioSciences, Inc. (PCRX) Investor Profile: Who’s Buying and Why?
Pacira BioSciences, Inc. (PCRX) Market Position & Future Outlook
Pacira BioSciences is strategically positioned in the pharmaceutical sector with a focus on non-opioid pain management and regenerative health solutions. The company's future outlook is shaped by its ability to expand its product portfolio, capitalize on market opportunities, and navigate industry challenges. For more insights into Pacira BioSciences' financial standing, you might find this resource helpful: Breaking Down Pacira BioSciences, Inc. (PCRX) Financial Health: Key Insights for Investors.
Competitive Landscape
| Company | Market Share, % | Key Advantage |
|---|---|---|
| Pacira BioSciences, Inc. | Estimated 15% - 20% in non-opioid pain management | Focus on innovative, non-opioid pain management solutions with products like EXPAREL. |
| Heron Therapeutics, Inc. | Estimated 10% - 15% in post-operative pain management | Proprietary Biochronomer drug delivery technology for extended-release products. |
| assertions Ltd. | Estimated 5% - 10% in regional anesthesia | Comprehensive portfolio of nerve blocks and regional anesthesia products. |
Opportunities & Challenges
| Opportunities | Risks |
|---|---|
| Expansion of EXPAREL into new indications and patient populations. | Regulatory hurdles and potential delays in drug approvals. |
| Strategic acquisitions to broaden product offerings and market reach. | Intense competition from generic drugs and alternative therapies. |
| Increased adoption of non-opioid pain management solutions due to opioid crisis. | Changes in healthcare policies and reimbursement models affecting pricing and access. |
Industry Position
Pacira BioSciences holds a significant position within the pharmaceutical industry, particularly in the niche market of non-opioid pain management. Here are some key aspects of their industry standing:
- Leader in Non-Opioid Pain Management: Pacira is recognized for its focus on developing and commercializing non-opioid alternatives for pain relief, addressing the growing demand for safer pain management options.
- EXPAREL's Market Dominance: EXPAREL, its flagship product, has gained substantial market share in postsurgical pain management, offering a longer-lasting alternative to traditional opioids.
- Strategic Acquisitions: Pacira has strategically acquired companies and technologies to expand its portfolio and strengthen its position in regenerative health.
- Focus on Innovation: The company continues to invest in research and development to introduce new and improved pain management solutions.
Pacira BioSciences, Inc. (PCRX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.